Vinorelbine Ditartrate

Cervical Cancer

UNICANCERSmall moleculePhase 2Dormant

BBB

72/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 95/ 100

Competitive context

159 Active assets in the Cervical Cancer cohort.

Asset / Sponsor	Phase	Rating
Tisotumab Vedotin Seagen Inc.	Phase 2	BB
CIS-DIAMMINEDICHLOROPLATINUM II Uganda Cancer Institute	Phase 3	B
Pembrolizumab Merck Sharp & Dohme LLC	Phase 3	B
Cyclophosphamide Merck Sharp & Dohme LLC	Phase 3	B
Carboplatin Merck Sharp & Dohme LLC	Phase 3	B

View all 50 →

Same molecule, other indications

Vinorelbine Ditartrate is also rated in:

Hodgkins lymphomaActive

BBB

Indicative · Phase 3

72 / 100

non-small cell lung carcinomaActive

BB

Indicative · Phase 4

70 / 100

lung large cell carcinomaActive

BB

Indicative · Phase 3

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.